Biomarker-Driven Lung Cancer | Clinical

The Relevance of MET Alterations to Targeted NSCLC Therapies

November 25, 2021

Martin Dietrich, MD, PhD, discusses the role MET alterations play as oncogenic drivers of non–small cell lung cancer.

Part 4: Whether to Switch Treatments After Discovery of MET Mutations in NSCLC

November 23, 2021

During a live virtual event, Martin Dietrich, MD, PhD, discusses how to address switching treatments in response to detection of a MET gene biomarker.

Part 3: Addressing Toxicities in MET Inhibitors for NSCLC

November 19, 2021

During a live virtual event, Martin Dietrich, MD, PhD, discusses management of toxicities and adverse events of MET inhibitors in non–small cell lung cancer.

Part 2: Choosing a Treatment for NSCLC with MET Exon 14 Skipping Mutation

November 17, 2021

At a live virtual event, Martin Dietrich, MD, PhD, discusses treatment options for a patient with non–small cell lung cancer when molecular testing shows a MET exon 14 skipping mutation.

Tepotinib Effective for MET+ NSCLC Found by Tissue or Liquid Biopsy

November 15, 2021

Giuseppe Giaccone, MD, PhD, discusses the results of the VISION trial of tepotinib in patients with non–small cell lung cancer.

Part 1: Challenges in Performing Biopsies and Molecular Testing in NSCLC

November 12, 2021

At a live virtual event, Martin Dietrich, MD, PhD, discusses how to approach biopsies and molecular testing in coordination with pathologists and testing services for patients with non–small cell lung cancer.

Bemcentinib for NSCLC Granted FDA Fast Track Designation

November 10, 2021

Bemcentinib is currently being studied in combination with pembrolizumab and has demonstrated a good safety profile.

PD-1 Assay to Determine Atezolizumab Eligibility Receives FDA Approval for Use in NSCLC

October 22, 2021

The assay is meant to determine patient eligibility for atezolizumab, which was granted FDA approval in PD-L1-positive lung cancer on October, 15. The assay was used in the IMpower010 study.

FDA Approves Adjuvant Atezolizumab for PD-L1+ Non–Small Cell Lung Cancer

October 15, 2021

Atezolizumab is now approved for the adjuvant treatment of NCSLC expressing PD-L1≥1%. The approval is based on the IMpower010 study.

FDA Grants Seventh Regulatory Designation to Repotrectinib for Solid Tumors, NSCLC

October 06, 2021

The breakthrough therapy designation marks the agents seventh regulatory designation.